Hyperlipoproteinemias:
Indications for: REPATHA
To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular (CV) disease. Adjunct to diet, alone or in combination with other lipid-lowering therapies, in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH]) to reduce LDL-C. Adjunct to diet and other LDL-lowering therapies, in patients with HeFH to reduce LDL-C. Adjunct to other LDL-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.
Adult Dosage:
Give by SC inj into abdomen, thigh, or upper arm; rotate inj sites. Primary hyperlipidemia, HeFH or CV disease: 140mg every 2 weeks or 420mg once monthly. HoFH: initially 420mg once monthly, may increase to 420mg every 2 weeks if response is not achieved in 12 weeks. On lipid apheresis: may initiate with 420mg every 2 weeks; give after session. Assess LDL-C levels as early as 4 weeks after initiation. Patients on once monthly dosing, measure LDL-C just prior to the next scheduled dose. To administer 420mg dose: give over 5mins by using the on-body infusor or as 3 inj consecutively within 30mins using the prefilled syringe or autoinjector.
Children Dosage:
Primary hyperlipidemia: not established. HeFH or HoFH: <10yrs: not established. Give by SC inj into abdomen, thigh, or upper arm; rotate inj sites. HeFH (≥10yrs): 140mg every 2 weeks or 420mg once monthly. HoFH (≥10yrs): initially 420mg once monthly, may increase to 420mg every 2 weeks if response is not achieved in 12 weeks. On lipid apheresis: may initiate with 420mg every 2 weeks; give after session. Assess LDL-C levels as early as 4 weeks after initiation. Patients on once monthly dosing, measure LDL-C just prior to the next scheduled dose. To administer 420mg dose: give over 5mins by using the on-body infusor or as 3 inj consecutively within 30mins using the prefilled syringe or autoinjector.
REPATHA Warnings/Precautions:
Do not inject into areas that are tender, bruised, red, or indurated. Discontinue if serious allergic reactions (eg, angioedema, rash, urticaria) occur. Latex allergy. Severe hepatic impairment. Pregnancy. Nursing mothers.
See Also:
REPATHA Classification:
Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.
REPATHA Interactions:
Avoid co-administration with other injectable drugs at same inj site.
Adverse Reactions:
Nasopharyngitis, URTI, influenza, back pain, inj site reactions.
Generic Drug Availability:
NO
How Supplied:
Single-use prefilled syringe—1; Single-use prefilled SureClick autoinjector—1, 2, 3; Single-use Pushtronex system—1
